Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis

References

• Tedaldi G, Tebaldi M, Zampiga V, Danesi R, Arcangeli V, Ravegnani M, et al. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. Oncotarget 2017;8:47064–47075.
   PubMed Web of Science ®Google Scholar
• Chen S, Cavazza E, Barlier C, Salleron J, Filhine-Tresarrieu P, Gavoilles C, et al. Beside P53 and PTEN: identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets. Oncol Lett 2016;12:3264–3272.
   PubMed Web of Science ®Google Scholar
• Tomar T, de Jong S, Alkema NG, Hoekman RL, Meersma GJ, Klip HG, et al. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. Genome Med 2016;8:107.
   PubMed Web of Science ®Google Scholar
• Nishida N, Murakami F, Higaki K. Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer. Pathol Int 2016;66:337–342.
   PubMed Web of Science ®Google Scholar
• Zeppernick F, Meinhold-Heerlein I, Shih IeM. Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma – an update. J Obstet Gynaecol Res 2015;41:6–11.
   PubMed Web of Science ®Google Scholar
• Wen J, Shi JL, Shen DH, Chen YX, Song QJ. Morphologic changes of fallopian tubal epithelium in ovarian serous tumors. Zhonghua Bing Li Xue Za Zhi 2012;41:433–437.
   PubMedGoogle Scholar
• Li J, Ning Y, Abushahin N, Yuan Z, Wang Y, Wang Y, et al. Secretory cell expansion with aging: risk for pelvic serous carcinogenesis. Gynecol Oncol 2013;131:555–560.
   PubMed Web of Science ®Google Scholar
• Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol 2010;222:110–116.
   PubMed Web of Science ®Google Scholar
• Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008;26:4160–4165.
   PubMed Web of Science ®Google Scholar
• Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 2004;23:35–40.
   PubMed Web of Science ®Google Scholar
• Leunen K, Legius E, Moerman P, Amant F, Neven P, Vergote I. Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. Int J Gynecol Cancer 2006;16:183–188.
   PubMed Web of Science ®Google Scholar
• Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451–456.
   PubMed Web of Science ®Google Scholar
• Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007;19:3–9.
   PubMed Web of Science ®Google Scholar
• Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008;53:127–138.
   PubMed Web of Science ®Google Scholar
• Mittal N, Srinivasan R, Gupta N, Rajwanshi A, Nijhawan R, Gautam U, et al. Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma. Indian J Pathol Microbiol 2016;59:481–488.
   PubMed Web of Science ®Google Scholar
• Li HX, Lu ZH, Shen K, Cheng WJ, Malpica A, Zhang J, et al. Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol 2014;7:848–857.
   PubMed Web of Science ®Google Scholar
• Iwabuchi T, Yoshimoto C, Shigetomi H, Kobayashi H. Oxidative stress and antioxidant defense in endometriosis and its malignant transformation. Oxid Med Cell Longev 2015;2015:848595.
   PubMed Web of Science ®Google Scholar
• Iwabuchi T, Yoshimoto C, Shigetomi H, Kobayashi H. Cyst fluid hemoglobin species in endometriosis and its malignant transformation: the role of metallobiology. Oncol Lett 2016;11:3384–3388.
   PubMed Web of Science ®Google Scholar
• Winarto H, Tan MI, Sadikin M, Wanandi SI. ARID1A expression is down-regulated by oxidative stress in endometriosis and endometriosis-associated ovarian cancer. Transl Oncogenomics 2017;9:1177272716689818.
   Google Scholar
• Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532–1543.
   PubMed Web of Science ®Google Scholar
• Cao YT, Li JH, Wang YT, Fu YW, Xu J. Serum ALDH1A1 is a tumor marker for the diagnosis of non-small cell lung cancer. Tumori 2014;100:214–218.
   PubMed Web of Science ®Google Scholar
• Kuhn E, Wang TL, Doberstein K, Bahadirli-Talbott A, Ayhan A, Sehdev AS, et al. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Mod Pathol 2016;29:1254–1261.
   PubMed Web of Science ®Google Scholar
• Chui MH, Wang Y, Wu RC, Seidman J, Kurman RJ, Wang TL, Shih IeM. Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Mod Pathol 2015;28:437–445.
   PubMed Web of Science ®Google Scholar
• Ning G, Bijron JG, Yamamoto Y, Wang X, Howitt BE, Herfs M, et al. The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. J Pathol 2014;234:478–487.
   PubMed Web of Science ®Google Scholar
• Sehgal R, Sheibani N, Rhodes SJ, Belecky Adams TL. BMP7 and SHH regulate Pax2 in mouse retinal astrocytes by relieving TLX repression. Dev Biol 2009;332:429–443.
   PubMed Web of Science ®Google Scholar
• Al-Hujaily EM, Tang Y, Yao DS, Carmona E, Garson K, Vanderhyden BC. Divergent roles of PAX2 in the etiology and progression of ovarian cancer. Cancer Prev Res (Phila) 2015;8:1163–1173.
   PubMed Web of Science ®Google Scholar
• Patrício P, Ramalho-Carvalho J, Costa-Pinheiro P, Almeida M, Barros-Silva JD, Vieira J, et al. Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis. J Cell Mol Med 2013;17:1048–1058.
   PubMed Web of Science ®Google Scholar
• Lee SB, Doberstein K, Baumgarten P, Wieland A, Ungerer C, Bürger C, et al. PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells. PLoS One 2011;6:e22312.
   PubMed Web of Science ®Google Scholar
• Jia N, Wang J, Li Q, Tao X, Chang K, Hua K, et al. DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer. Oncotarget 2016;7:84785–84797.
   PubMed Web of Science ®Google Scholar
• Modi DA, Tagare RD, Karthikeyan S, Russo A, Dean M, Davis DA, et al. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer. Oncogene 2017;36:3015–3024.
   PubMed Web of Science ®Google Scholar
• Auersperg N. The stem-cell profile of ovarian surface epithelium is reproduced in the oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae. Int J Gynecol Pathol 2013;32:444–453.
   PubMed Web of Science ®Google Scholar
• Okudela K, Woo T, Mitsui H, Suzuki T, Tajiri M, Sakuma Y, et al. Downregulation of ALDH1A1 expression in non-small cell lung carcinomas – its clinicopathologic and biological significance. Int J Clin Exp Pathol 2013;6:1–12.
   PubMed Web of Science ®Google Scholar
• Tomita H, Tanaka K, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 2016;7:11018–11032.
   PubMed Web of Science ®Google Scholar
• Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, et al. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 2012;30:2100–2113.
   PubMed Web of Science ®Google Scholar
• Fernandes ND, Sun Y, Price BD. Activation of the kinase activity of ATM by retinoic acid is required for CREB-dependent differentiation of neuroblastoma cells. J Biol Chem 2007;282:16577–16584.
   PubMed Web of Science ®Google Scholar
• Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG. EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol 2011;24:786–793.
   PubMed Web of Science ®Google Scholar
• Beca F, Kensler K, Glass B, Schnitt SJ, Tamimi RM, Beck AH. EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses’ Health Studies. Breast Cancer Res 2017;19:21.
   PubMed Web of Science ®Google Scholar
• Han Li C, Chen Y. Targeting EZH2 for cancer therapy: progress and perspective. Curr Protein Pept Sci 2015;16:559–570.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 2011;19:86–100.
   PubMed Web of Science ®Google Scholar
• Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL, Drapkin R. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011;123:5–12.
   PubMed Web of Science ®Google Scholar
• Jeon TY, Han ME, Lee YW, Lee YS, Kim GH, Song GA, et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 2010;102:710–718.
   PubMed Web of Science ®Google Scholar
• Karst AM, Jones PM, Vena N, Ligon AH, Liu JF, Hirsch MS, et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res 2014;74:1141–1152.
   PubMed Web of Science ®Google Scholar
• Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010;116:2621–2634.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhou Y, Reske SN, Shen C. PTEN mutation: many birds with one stone in tumorigenesis. Anticancer Res 2008;28:3613–3619.
   PubMed Web of Science ®Google Scholar
• Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013;24:751–765.
   PubMed Web of Science ®Google Scholar
• Garg R, Blando JM, Perez CJ, Abba MC, Benavides F, Kazanietz MG. Protein kinase C epsilon cooperates with PTEN loss for prostate tumorigenesis through the CXCL13-CXCR5 pathway. Cell Rep 2017;19:375–388.
   PubMed Web of Science ®Google Scholar
• Gào X, Schöttker B. Reduction–oxidation pathways involved in cancer development: a systematic review of literature reviews. Oncotarget 2017;8:51888–51906.
   PubMed Web of Science ®Google Scholar
• Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, et al. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One 2012;7(9):e45484.
   PubMed Web of Science ®Google Scholar
• Bartlett TE, Chindera K, McDermott J, Breeze CE, Cooke WR, Jones A, et al. Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. Nat Commun 2016;7:11620.
   PubMed Web of Science ®Google Scholar
• Shigeta S, Toyoshima M, Kitatani K, Ishibashi M, Usui T, Yaegashi N. Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer. Oncogene 2016;35:3577–3586.
   PubMed Web of Science ®Google Scholar
• Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155–168.
   PubMed Web of Science ®Google Scholar
• Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316–323.
   PubMed Web of Science ®Google Scholar
• Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005;11:63–70.
   PubMed Web of Science ®Google Scholar
• Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11:321–333.
   PubMed Web of Science ®Google Scholar
• Wu R, Baker SJ, Hu TC, Norman KM, Fearon ER, Cho KR. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol 2013;182:1391–1399.
   PubMed Web of Science ®Google Scholar
• Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC. Conditional inactivation of BRCA1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 2007;313:133–145.
   PubMed Web of Science ®Google Scholar
• Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC. Conditional inactivation of BRCA1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One 2009;4:e8534.
   PubMed Web of Science ®Google Scholar
• Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003;63:3459–3463.
   PubMed Web of Science ®Google Scholar
• Mullany LK, Fan HY, Liu Z, White LD, Marshall A, Gunaratne P, et al. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 2011;30:3522–3536.
   PubMed Web of Science ®Google Scholar
• Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of BRCA1 and p53. PLoS One 2009;4:e8404.
   PubMed Web of Science ®Google Scholar
• Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, et al. Perturbation of Rb, p53, and BRCA1 or BRCA2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 2012;72:4141–4153.
   PubMed Web of Science ®Google Scholar
• Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 2012;122:553–557.
   PubMed Web of Science ®Google Scholar
• Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 2012;109:3921–3926.
   PubMed Web of Science ®Google Scholar
• Sapoznik S, Bahar-Shany K, Brand H, Pinto Y, Gabay O, Glick-Saar E, et al. Activation-induced cytidine deaminase links ovulation-induced inflammation and serous carcinogenesis. Neoplasia 2016;18:90–99.
   PubMed Web of Science ®Google Scholar
• Kobayashi H. Potential scenarios leading to ovarian cancer arising from endometriosis. Redox Rep 2016;21:119–126.
   PubMed Web of Science ®Google Scholar
• Ameziane-El-Hassani R, Dupuy C. Detection of reactive oxygen species in cells undergoing oncogene-induced senescence. Methods Mol Biol 2017;1534:139–145.
   PubMedGoogle Scholar
• Akatsuka S, Yamashita Y, Ohara H, Liu YT, Izumiya M, Abe K, et al. Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS One 2012;7:e43403.
   PubMed Web of Science ®Google Scholar
• Jiang L, Zhong Y, Akatsuka S, Liu YT, Dutta KK, Lee WH, et al. Deletion and single nucleotide substitution at G:C in the kidney of gpt delta transgenic mice after ferric nitrilotriacetate treatment. Cancer Sci 2006;97:1159–1167.
   PubMed Web of Science ®Google Scholar
• Shigetomi H, Tsunemi T, Haruta S, Kajihara H, Yoshizawa Y, Tanase Y, et al. Molecular mechanisms linking endometriosis under oxidative stress with ovarian tumorigenesis and therapeutic modalities. Cancer Invest 2012;30:473–480.
   PubMed Web of Science ®Google Scholar
• Jardim DLF, Tang C, Gagliato DDM, Falchook GS, Hess K, Janku F, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res 2014;20:6336–6345.
   PubMed Web of Science ®Google Scholar
• Jones NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, Burke WM, Tergas AI, et al. Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. Int J Cancer 2017;140:1396–1404.
   PubMed Web of Science ®Google Scholar
• King SM, Hilliard TS, Wu LY, Jaffe RC, Fazleabas AT, Burdette JE. The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr Relat Cancer 2011;18:627–642.
   PubMed Web of Science ®Google Scholar
• Senthil K, Aranganathan S, Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta 2004;339:27–32.
   PubMed Web of Science ®Google Scholar
• Chua AC, Klopcic B, Lawrance IC, Olynyk JK, Trinder D. Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol 2010;16:663–672.
   PubMed Web of Science ®Google Scholar